Cancer Cachexia: Mechanisms and Clinical Implications

Cachexia is a multifactorial process of skeletal muscle and adipose tissue atrophy resulting in progressive weight loss. It is associated with poor quality of life, poor physical function, and poor prognosis in cancer patients. It involves multiple pathways: procachectic and proinflammatory signals from tumour cells, systemic inflammation in the host, and widespread metabolic changes (increased resting energy expenditure and alterations in metabolism of protein, fat, and carbohydrate). Whether it is primarily driven by the tumour or as a result of the host response to the tumour has yet to be fully elucidated. Cachexia is compounded by anorexia and the relationship between these two entities has not been clarified fully. Inconsistencies in the definition of cachexia have limited the epidemiological characterisation of the condition and there has been slow progress in identifying therapeutic agents and trialling them in the clinical setting. Understanding the complex interplay of tumour and host factors will uncover new therapeutic targets.

[1]  O. Ukkola [Cachexia]. , 2020, Duodecim; laaketieteellinen aikakauskirja.

[2]  V. Ruíz García,et al.  Megestrol acetate for treatment of anorexia-cachexia syndrome. , 2013, The Cochrane database of systematic reviews.

[3]  F. Bozzetti Basics in Clinical Nutrition: Nutritional support in cancer , 2010 .

[4]  C. Loprinzi,et al.  A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). , 2010, Lung cancer.

[5]  S. Anker,et al.  Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference , 2010, Expert opinion on investigational drugs.

[6]  M. DeBoer Update on melanocortin interventions for cachexia: progress toward clinical application. , 2010, Nutrition.

[7]  P. Contu,et al.  Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. , 2010, The oncologist.

[8]  K. Fox,et al.  Estimation of Cachexia among Cancer Patients Based on Four Definitions , 2009, Journal of oncology.

[9]  D. McMillan Systemic inflammation, nutritional status and survival in patients with cancer , 2009, Current opinion in clinical nutrition and metabolic care.

[10]  M. Tisdale Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[11]  S. Paterson-Brown,et al.  The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer , 2009, British Journal of Cancer.

[12]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[13]  G. Lynch,et al.  The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. , 2008, Pharmacology & therapeutics.

[14]  F. Strasser Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue , 2008, Current opinion in clinical nutrition and metabolic care.

[15]  D. McMillan,et al.  An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer , 2008, Proceedings of the Nutrition Society.

[16]  P. Contu,et al.  Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. , 2008, Nutrition.

[17]  H. Friess,et al.  Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[18]  Keith W. Whitaker,et al.  Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1β administration , 2008, Neuropharmacology.

[19]  L. Kachnic,et al.  A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122) , 2008, Supportive Care in Cancer.

[20]  Georg Endler,et al.  C-reactive protein and all-cause mortality in a large hospital-based cohort. , 2008, Clinical chemistry.

[21]  C. Dejong,et al.  Pathophysiology of cancer cachexia: much more than host-tumour interaction? , 2007, Clinical nutrition.

[22]  D. Alberts,et al.  Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[23]  I. Bosaeus,et al.  Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive Cachexia , 2007, Clinical Cancer Research.

[24]  P. Novotny,et al.  A placebo‐controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome , 2007, Cancer.

[25]  G. Filippatos,et al.  Is There a Human Homologue to the Murine Proteolysis-Inducing Factor? , 2007, Clinical Cancer Research.

[26]  A. Rossi,et al.  Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. , 2007, The Lancet. Oncology.

[27]  R. Skipworth,et al.  Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. , 2007, Journal of pain and symptom management.

[28]  D. Marks,et al.  Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. , 2007, Endocrinology.

[29]  I. Bosaeus,et al.  Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning , 2007, Clinical Cancer Research.

[30]  P. Beale,et al.  Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial , 2007, Supportive Care in Cancer.

[31]  B. Higgins,et al.  Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. , 2007, The Cochrane database of systematic reviews.

[32]  S. Paterson-Brown,et al.  Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer , 2006, British Journal of Cancer.

[33]  E. Bruera,et al.  Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. , 2006, The American journal of clinical nutrition.

[34]  F. Strasser,et al.  Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Fritsche Fatty acids as modulators of the immune response. , 2006, Annual review of nutrition.

[36]  K. Fearon,et al.  Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. , 2006, The American journal of clinical nutrition.

[37]  M. Muscaritoli,et al.  IGF-1 is downregulated in experimental cancer cachexia. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[38]  G. Bodoky,et al.  ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. , 2006, Clinical nutrition.

[39]  C. Dejong,et al.  Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. , 2005, The international journal of biochemistry & cell biology.

[40]  N. Christakis,et al.  Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Helmut Friess,et al.  Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia , 2005, Clinical Cancer Research.

[42]  P. Ravasco,et al.  Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy , 2005, Head & neck.

[43]  Patrick Schrauwen,et al.  Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. , 2005, Oncology reports.

[44]  Brock T Brown,et al.  The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. , 2005, Endocrinology.

[45]  S. Paterson-Brown,et al.  Serum parathyroid hormone‐related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma , 2005, Cancer.

[46]  S. Wigmore,et al.  Systemic inflammation, cachexia and prognosis in patients with cancer , 2005, Current opinion in clinical nutrition and metabolic care.

[47]  P. Goggin,et al.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial , 2005, Gut.

[48]  P. Ravasco,et al.  Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Jen,et al.  Characterization of a Human Homologue of Proteolysis-Inducing Factor and Its Role in Cancer Cachexia , 2004, Clinical Cancer Research.

[50]  D. Krieger,et al.  Correlation Between Ammonia Levels and the Severity of Hepatic Encephalopathy , 2004 .

[51]  Max Dahele,et al.  Research methodology: cancer cachexia syndrome , 2004, Palliative medicine.

[52]  A. Asakawa,et al.  Cancer anorexia-cachexia syndrome: cytokines and neuropeptides , 2004, Current opinion in clinical nutrition and metabolic care.

[53]  P. Novotny,et al.  An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Herdman,et al.  Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. , 2004, Journal of pain and symptom management.

[55]  Paula Ravasco,et al.  Cancer: disease and nutrition are key determinants of patients’ quality of life , 2004, Supportive Care in Cancer.

[56]  K. Fearon,et al.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids , 2004, British Journal of Cancer.

[57]  I. Bosaeus,et al.  Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. , 2004, International journal of oncology.

[58]  N. Aaronson,et al.  Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial , 2003, Gut.

[59]  M. Tisdale,et al.  Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB , 2003, British Journal of Cancer.

[60]  N. Macdonald,et al.  Understanding and managing cancer cachexia. , 2003, Journal of the American College of Surgeons.

[61]  C. McArdle,et al.  A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. , 2003, Lung cancer.

[62]  F. López‐Soriano,et al.  Cancer cachexia: the molecular mechanisms. , 2003, The international journal of biochemistry & cell biology.

[63]  Tim Cheetham,et al.  Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. , 2003, The New England journal of medicine.

[64]  P. Goggin,et al.  Thalidomide and its derivatives: emerging from the wilderness , 2003, Postgraduate medical journal.

[65]  B. Glimelius,et al.  The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. , 2002, Anticancer research.

[66]  G. Biolo,et al.  Regulation of muscle cathepsin B proteolytic activity in protein-depleted patients with chronic diseases. , 2002, Clinical nutrition.

[67]  T. Zimmers,et al.  Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.

[68]  P. Lissoni Is there a role for melatonin in supportive care? , 2002, Supportive Care in Cancer.

[69]  P. Novotny,et al.  Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  P. Dagnelie,et al.  Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  D. Ferrigno,et al.  Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. , 2001, Lung cancer.

[72]  J. Kamegai,et al.  Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. , 2001, Diabetes.

[73]  D. Chinkes,et al.  Reversal of catabolism by beta-blockade after severe burns. , 2001, The New England journal of medicine.

[74]  T. Lipman,et al.  AGA technical review on parenteral nutrition. , 2001, Gastroenterology.

[75]  M. Tisdale,et al.  Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF) , 2001, British Journal of Cancer.

[76]  I. Waddell,et al.  Proteolysis‐inducing factor regulates hepatic gene expression via the transcription factors NF‐κΒ and STAT3 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[77]  R. Cone,et al.  Role of the central melanocortin system in cachexia. , 2001, Cancer research.

[78]  M. Nakazato,et al.  A role for ghrelin in the central regulation of feeding , 2001, Nature.

[79]  S. Meijsing,et al.  Cancer cachexia: A therapeutic approach , 2001, Medicinal research reviews.

[80]  M. Tisdale,et al.  Effect of the specific cyclooxygenase‐2 inhibitor meloxicam on tumour growth and cachexia in a murine model , 2000, International journal of cancer.

[81]  C. Garcı́a-Martı́nez,et al.  Calpain-3 gene expression is decreased during experimental cancer cachexia. , 2000, Biochimica et biophysica acta.

[82]  C. McArdle,et al.  Prognostic Factors in Advanced Gastrointestinal Cancer Patients With Weight Loss , 2000, Nutrition and cancer.

[83]  J. Ross,et al.  Effect of Oral Eicosapentaenoic Acid on Weight Loss in Patients With Pancreatic Cancer , 2000, Nutrition and cancer.

[84]  K. Lundholm,et al.  Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. , 2000, European journal of cancer.

[85]  P. Novotny,et al.  Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  K. Fearon,et al.  Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. , 1999, International journal of oncology.

[87]  A. Inui,et al.  Cancer anorexia-cachexia syndrome: are neuropeptides the key? , 1999, Cancer research.

[88]  K. Fearon,et al.  The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer , 1999, British Journal of Cancer.

[89]  L. Mariani,et al.  Artificial Nutrition in Cancer Patients: Which Route, What Composition? , 1999, World Journal of Surgery.

[90]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[91]  M. Tisdale,et al.  Catabolism of adipose tissue by a tumour‐produced lipid‐mobilising factor , 1999, International journal of cancer.

[92]  M. Tisdale,et al.  Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. , 1998, Cancer research.

[93]  M. Tisdale,et al.  Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. , 1998, Cancer research.

[94]  M. Tisdale,et al.  Purification and characterization of a tumor lipid-mobilizing factor. , 1998, Cancer research.

[95]  A. Norman,et al.  Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? , 1998, European journal of cancer.

[96]  R. Seeley,et al.  Melanocortin receptors in leptin effects , 1997, Nature.

[97]  V. Rivera,et al.  Transcriptional squelching re-examined , 1997, Nature.

[98]  E. Bruera ABC of palliative care: Anorexia, cachexia, and nutrition , 1997 .

[99]  G. Barsh,et al.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.

[100]  S. Barni,et al.  A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first‐line treatment of advanced non‐small cell lung cancer patients in a poor clinical state , 1997, Journal of pineal research.

[101]  G. Mantovani,et al.  Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. , 1997, European journal of cancer.

[102]  J. Fischer,et al.  Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y , 1996, Peptides.

[103]  K. Fearon,et al.  Characterization of a cancer cachectic factor , 1996, Nature.

[104]  J. O'fallon,et al.  Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  J. Ross,et al.  Acute‐phase protein response and survival duration of patients with pancreatic cancer , 1995, Cancer.

[106]  K. Yasumoto,et al.  Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. , 1995, Cancer research.

[107]  P. Reeds,et al.  Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? , 1994, The Journal of nutrition.

[108]  D. McMillan,et al.  Protein synthesis in cancer patients with inflammatory response: investigations with [15N]glycine. , 1994, Nutrition.

[109]  J. Ross,et al.  Cytokines, the Acute‐Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic Cancer , 1994, Annals of surgery.

[110]  M. Papa,et al.  Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.

[111]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[112]  G. Strassmann,et al.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.

[113]  D. Schaid,et al.  A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia , 1990, Cancer.

[114]  S. Jonjić,et al.  Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes , 1989, The Journal of experimental medicine.

[115]  J. Norton,et al.  Body cell mass in cancer-bearing and anorexic patients. , 1987, JPEN. Journal of parenteral and enteral nutrition.

[116]  R. Chlebowski,et al.  Influence of nandrolone decanoate on weight loss in advanced non‐small cell lung cancer , 1986, Cancer.

[117]  R. Makuch,et al.  Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. , 1985, Cancer research.

[118]  E. Bruera,et al.  Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. , 1985, Cancer treatment reports.

[119]  K. Calman,et al.  Prednisolone as an appetite stimulant in patients with cancer. , 1984, British medical journal.

[120]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[121]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[122]  R. Hahn,et al.  Corticosteroid therapy of preterminal gastrointestinal cancer , 1974, Cancer.

[123]  M. Muscaritoli,et al.  New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'. , 2008, Asia Pacific journal of clinical nutrition.

[124]  M. Guarcello,et al.  EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life , 2007 .

[125]  P. Loehrer Comparison of Orally Administered Cannabis Extract and Delta-9 Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group , 2007 .

[126]  M. Elia,et al.  Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. , 2006, International journal of oncology.

[127]  Z. Ortiz,et al.  Megestrol acetate for the treatment of anorexia-cachexia syndrome. , 2005, The Cochrane database of systematic reviews.

[128]  Rocco Barazzoni,et al.  Metabolic consequences of physical inactivity. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[129]  E. Bruera,et al.  Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  C. McArdle,et al.  Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. , 1999, Nutrition and cancer.

[131]  K. Fearon,et al.  Cancer cachexia. , 1999, Surgical oncology.

[132]  D. Heber,et al.  Clinical aspects of nutrition in advanced cancer. , 1992, Oncology.

[133]  G. Opdenakker,et al.  Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. , 1991, European journal of cancer.

[134]  K. Lundholm,et al.  Elevated energy expenditure in cancer patients with solid tumours. , 1991, European journal of cancer.

[135]  L. Moldawer,et al.  Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. , 1991, Cancer research.